Assessment of a new point-of-care system for detection of prostate specific antigen

被引:4
|
作者
Rausch, Steffen [1 ]
Hennenlotter, Joerg [1 ]
Wiesenreiter, Josef [1 ]
Hohneder, Andrea [1 ]
Heinkele, Julian [1 ]
Schwentner, Christian [1 ]
Stenzl, Arnulf [1 ]
Todenhofer, Tilman [1 ,2 ]
机构
[1] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany
[2] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
来源
BMC UROLOGY | 2016年 / 16卷
关键词
Point-of-care; Prostate cancer; Prostate specific antigen; CANCER PATIENTS; TOTAL PSA; HYPERPLASIA; MEN; PREDICTOR; RELAPSE; VOLUME; BLOOD; RISK;
D O I
10.1186/s12894-016-0119-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Measurement of the prostate specific antigen (PSA) remains an important tool in prostate cancer (PC) diagnosis. Due to limited availability of laboratory devices in an outpatient setting, compact and easy-to-handle point-of-care (POC) systems are desirable. Recently, a chip for PSA measurement on the concile (R) Omega 100 POC reader platform was introduced. To investigate the clinical applicability, we evaluated the system in a consecutive cohort of patients undergoing PSA measurement in our outpatient clinic. Methods: Between 07/2014 and 01/2015, PSA was analyzed in a total of 198 patients by the POC reader system and in parallel by an Immulite 2000 (R) and Centaur (R) standard laboratory system, respectively. By standard (Immulite (R)) measurement, 67 (34,2 %) had PSA > 4 ng/ml and 131 (65,8 %) had PSA = 4 ng/ml. Results were correlated by linear regression analyses for all patients and within PSA subgroups. For patients with available prostate histology after PSA measurement (n = 68), receiver-operating characteristic curves were created and area under the curve (AUC), sensitivity and specificity for the prediction of PC at best cut-off value were calculated. Results: The coefficients of determination (r(2)) for the POC device compared to laboratory testing were 0.72 (Immulite (R)) and 0.63 (Centaur (R)), respectively (both p < 0.0001). In the PSA range of = 4 ng/ml, the observed correlations were 0.75 and 0.70, respectively. For the POC test system, AUC for detection of PC was calculated with 0.745 while the standard laboratory tests showed 0.778 (Immulite (R)) and 0.771 (Centaur (R)). At best cut-off of 3.64 ng/ml, PSA analysis by the POC system showed a sensitivity of 85.7 % and a specificity of 66.7 %. Conclusions: The POC system obtained good concordance to elaborate laboratory measurement. In a screening scenario, the system provides quick and reliable PSA measurement, especially in the PSA range up to 4 ng/ml.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A new point-of-care test for the rapid detection of urinary tract infections
    Arienzo, Alyexandra
    Cellitti, Valentina
    Ferrante, Valeria
    Losito, Francesca
    Stalio, Ottavia
    Murgia, Lorenza
    Marino, Rossella
    Cristofano, Flavia
    Orru, Michela
    Visca, Paolo
    Di Somma, Salvatore
    Silvestri, Lorena
    Ziparo, Vincenzo
    Antonini, Giovanni
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020, 39 (02) : 325 - 332
  • [42] A new point-of-care test for the rapid detection of urinary tract infections
    Alyexandra Arienzo
    Valentina Cellitti
    Valeria Ferrante
    Francesca Losito
    Ottavia Stalio
    Lorenza Murgia
    Rossella Marino
    Flavia Cristofano
    Michela Orrù
    Paolo Visca
    Salvatore Di Somma
    Lorena Silvestri
    Vincenzo Ziparo
    Giovanni Antonini
    European Journal of Clinical Microbiology & Infectious Diseases, 2020, 39 : 325 - 332
  • [43] A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection
    Annese, Valerio F.
    Patil, Samadhan B.
    Hu, Chunxiao
    Giagkoulovits, Christos
    Al-Rawhani, Mohammed A.
    Grant, James
    Macleod, Martin
    Clayton, David J.
    Heaney, Liam M.
    Daly, Ronan
    Accarino, Claudio
    Shah, Yash D.
    Cheah, Boon C.
    Beeley, James
    Evans, Thomas R. Jeffry
    Jones, Robert
    Barrett, Michael P.
    Cumming, David R. S.
    MICROSYSTEMS & NANOENGINEERING, 2021, 7 (01)
  • [44] A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection
    Valerio F. Annese
    Samadhan B. Patil
    Chunxiao Hu
    Christos Giagkoulovits
    Mohammed A. Al-Rawhani
    James Grant
    Martin Macleod
    David J. Clayton
    Liam M. Heaney
    Ronan Daly
    Claudio Accarino
    Yash D. Shah
    Boon C. Cheah
    James Beeley
    Thomas R. Jeffry Evans
    Robert Jones
    Michael P. Barrett
    David R. S. Cumming
    Microsystems & Nanoengineering, 7
  • [45] Specific IgE point-of-care testing is evolving
    Barnes, Charles S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (04) : 415 - 416
  • [46] The Role of Point-of-Care Testing in Specific Populations
    Yared, Nicholas
    CLINICS IN LABORATORY MEDICINE, 2023, 43 (02) : 181 - 187
  • [47] Point-of-care detection devices for wound care and monitoring
    Huang, Shu-Wei
    Wu, Yu-Feng
    Ahmed, Tanvir
    Pan, Shin-Chen
    Cheng, Chao-Min
    TRENDS IN BIOTECHNOLOGY, 2024, 42 (01) : 74 - 90
  • [48] DETECTION OF PROSTATE SPECIFIC ANTIGEN BY ELISA
    JOHNSON, ED
    KOTOWSKI, TM
    JOURNAL OF FORENSIC SCIENCES, 1993, 38 (02) : 250 - 258
  • [49] What Is New in Point-of-Care Testing?
    Melanson, Stacy E. F.
    POINT OF CARE, 2009, 8 (04): : 166 - 170
  • [50] What Is New in Point-of-Care Testing?
    Melanson, Stacy E. F.
    POINT OF CARE, 2007, 6 (02): : 144 - 146